Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. Yang C. and Merlin D. 2019. Int J Nanomedicine. 14: 8875–8889.

Inflammatory bowel disease (IBD) is an inflammatory condition of the gastrointestinal tract that has been treated traditionally using high doses of medicines, including antibiotics, non-steroidal anti-inflammatory drugs, biologics, and immunomodulators. While some of these drugs can ease early-stage inflammatory symptoms, they produce side effects that impair their use for long-term treatments. In the last years, drugs based on nanoparticles (NP) have arisen as a strategy to build drug delivery systems that can overcome these limitations. Several projects featuring this innovation have entered clinical trials for the treatment of IBD and are showing promising results. 

In this review, the authors analyse the current state of the research in NP drugs for treating inflammation. Specifically, topics such as the major administration routes for treating IBD or the targets for addressing intestinal inflammation at a cellular or tissue level. Finally, current challenges and future directions in the study of NP-mediated strategies to treat IBD are discussed.

 

Studies of Nanoparticle Delivery With in vitro Bio-Engineered Microtissues. Sun. M et al. 2020. Bioactive Materials, 5, 4, 924-937.

Several research initiatives such as New Deal are considering IBD treatments that imply bringing drugs directly to the intestines. Nanoparticles are a promising strategy for the development of drug-delivery vehicles. Currently, there is a wide variety of nanoparticles available, including lipidic, polymeric, gold-based or biomimetic nanoparticles. In order to assess the efficacy of these delivery systems, in vitro testing is crucial, as it allows for real-time and quantitative analyses that are difficult to conduct in vivo

In this review you will find an analysis of the different types of nanoparticle vehicles, their application areas and the alternatives to improve their delivery efficiency. In particular, this publication highlights multicellular spheroids and other 3D tissue engineering approaches that may provide innovative experimental platforms to develop new drug delivery systems to treat diseases such as IBD.